GlassScriptPhysician profile
Ranjeeta Mani
NPI 1780889592
$3,572.29
in general payments reported to CMS, 2019-2025
26 companies · $381 in 2025
The $381 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.57 · 2020: $42.90 · 2021: $397 · 2022: $803 · 2023: $409 · 2024: $1,485 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727 · Travel and Lodging: $548 · Education: $0.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.76 |
| Travel and Lodging | $547.65 |
| Education | $0.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,489.14 | 2022-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Sk Life Science, INC. | $583.26 | 2023-2025 | Xcopri |
| Ucb, INC. | $237.56 | 2021-2025 | Fintepla |
| Aucta Pharmaceuticals, INC. | $163.27 | 2024-2025 | Motpoly Xr |
| Eisai INC. | $130.06 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $120.61 | 2021-2022 | |
| Aquestive Therapeutics, INC. | $117.35 | 2019-2022 | |
| Boston Scientific Corporation | $78.73 | 2024-2025 | Lux-Dx Insertable Cardiac Monitor |
| Harmony Biosciences LLC | $76.80 | 2022-2024 | |
| Abbott Laboratories | $61.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $48.72 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $48.52 | 2025 | Daybue |
| Sumitomo Pharma America, INC. | $45.93 | 2023 | Aptiom |
| Scpharmaceuticals INC. | $41.90 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $41.44 | 2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $40.94 | 2023 | Inspire |
| Redhill Biopharma INC. | $37.91 | 2021-2022 | |
| Averitas Pharma INC. | $30.88 | 2025 | Qutenza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.36 | 2022 | |
| Amgen INC. | $24.56 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $24.27 | 2019 | |
| Shield Therapeutics INC | $23.71 | 2023 | Accrufer |
| Alnylam Pharmaceuticals INC. | $22.68 | 2024 | Onpattro |
| Zoll Respicardia, INC. | $21.35 | 2024 | Remede System |
| Argenx US, INC. | $19.40 | 2023 | Vyvgart |
| Pfizer INC. | $15.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranjeeta Mani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.